The Europe Drug Discovery Informatics Market would witness market growth of 9.9% CAGR during the forecast period (2024-2031).
The Germany market dominated the Europe Drug Discovery Informatics Market by Country in 2023 and would continue to be a dominant market till 2031; thereby, achieving a market value of $418.8 million by 2031. The UK market is exhibiting a CAGR of 9% during (2024 - 2031). Additionally, The France market would experience a CAGR of 10.7% during (2024 - 2031).
Informatics platforms facilitate the integration and analysis of diverse biological data sources, allowing researchers to gain insights into disease mechanisms, identify biomarkers, and prioritize drug candidates for further development. Furthermore, informatics-driven approaches enhance decision-making and resource allocation throughout the drug discovery pipeline, ultimately accelerating the development of novel therapies and reducing the time and cost of bringing new drugs to market. As the pharmaceutical industry embraces digital transformation, drug discovery informatics is poised to be increasingly critical in driving innovation and addressing unmet medical needs.
The drug discovery informatics market is leading in shaping research and development, leveraging cutting-edge computational and informational technologies to accelerate bringing new therapeutics to market. With the growing complexity of diseases and the need for more efficient drug development processes, drug discovery informatics has emerged as a critical enabler of innovation and efficiency in the pharmaceutical industry. Drug discovery informatics encompasses diverse computational tools, data analysis techniques, and informatics platforms that facilitate various stages of the drug discovery pipeline, from target identification and validation to lead optimization, preclinical studies, and beyond.
Several European countries have launched research and development (R&D) initiatives to foster innovation in healthcare and pharmaceuticals. Horizon Europe is the EU's flagship research and innovation program, with an over €95 billion budget for 2021-2027. It aims to support R&D in various sectors, including healthcare and pharmaceuticals, to address societal challenges and drive economic growth.
The European market for drug discovery informatics is experiencing significant expansion, buoyed by the region's robust healthcare infrastructure and substantial investments in medical devices and technology. Spain, a key player in this arena, boasts a thriving medical devices sector valued at USD 7.4 billion in 2021. The country's substantial healthcare budget of Euro 122.8 billion in 2020, with a notable 70% coming from public sources, underscores its commitment to advancing healthcare services. With an average per capita expenditure of Euro 2,594, Spain provides a fertile ground for adopting innovative healthcare technologies, including drug discovery informatics.
Based on Application, the market is segmented into Drug Discovery, and Drug Development. Based on Function, the market is segmented into Sequencing & Target Data Analysis, Molecular Modelling, Library & Database Preparation, Docking, and Others. Based on End User, the market is segmented into Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The Germany market dominated the Europe Drug Discovery Informatics Market by Country in 2023 and would continue to be a dominant market till 2031; thereby, achieving a market value of $418.8 million by 2031. The UK market is exhibiting a CAGR of 9% during (2024 - 2031). Additionally, The France market would experience a CAGR of 10.7% during (2024 - 2031).
Informatics platforms facilitate the integration and analysis of diverse biological data sources, allowing researchers to gain insights into disease mechanisms, identify biomarkers, and prioritize drug candidates for further development. Furthermore, informatics-driven approaches enhance decision-making and resource allocation throughout the drug discovery pipeline, ultimately accelerating the development of novel therapies and reducing the time and cost of bringing new drugs to market. As the pharmaceutical industry embraces digital transformation, drug discovery informatics is poised to be increasingly critical in driving innovation and addressing unmet medical needs.
The drug discovery informatics market is leading in shaping research and development, leveraging cutting-edge computational and informational technologies to accelerate bringing new therapeutics to market. With the growing complexity of diseases and the need for more efficient drug development processes, drug discovery informatics has emerged as a critical enabler of innovation and efficiency in the pharmaceutical industry. Drug discovery informatics encompasses diverse computational tools, data analysis techniques, and informatics platforms that facilitate various stages of the drug discovery pipeline, from target identification and validation to lead optimization, preclinical studies, and beyond.
Several European countries have launched research and development (R&D) initiatives to foster innovation in healthcare and pharmaceuticals. Horizon Europe is the EU's flagship research and innovation program, with an over €95 billion budget for 2021-2027. It aims to support R&D in various sectors, including healthcare and pharmaceuticals, to address societal challenges and drive economic growth.
The European market for drug discovery informatics is experiencing significant expansion, buoyed by the region's robust healthcare infrastructure and substantial investments in medical devices and technology. Spain, a key player in this arena, boasts a thriving medical devices sector valued at USD 7.4 billion in 2021. The country's substantial healthcare budget of Euro 122.8 billion in 2020, with a notable 70% coming from public sources, underscores its commitment to advancing healthcare services. With an average per capita expenditure of Euro 2,594, Spain provides a fertile ground for adopting innovative healthcare technologies, including drug discovery informatics.
Based on Application, the market is segmented into Drug Discovery, and Drug Development. Based on Function, the market is segmented into Sequencing & Target Data Analysis, Molecular Modelling, Library & Database Preparation, Docking, and Others. Based on End User, the market is segmented into Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
List of Key Companies Profiled
- Oracle Corporation
- Accenture PLC
- Thermo Fisher Scientific, Inc.
- Boehringer Ingelheim International GmbH
- Infosys Limited
- Charles River Laboratories International, Inc.
- Agilent Technologies, Inc.
- Illumina, Inc.
- Certara, Inc.
- Jubilant Pharmova Limited
Market Report Segmentation
By Application- Drug Discovery
- Drug Development
- Sequencing & Target Data Analysis
- Molecular Modelling
- Library & Database Preparation
- Docking
- Others
- Pharmaceutical Companies
- Biotechnology Companies
- Contract Research Organizations
- Others
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. Europe Drug Discovery Informatics Market by Application
Chapter 6. Europe Drug Discovery Informatics Market by Function
Chapter 7. Europe Drug Discovery Informatics Market by End User
Chapter 8. Europe Drug Discovery Informatics Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Oracle Corporation
- Accenture PLC
- Thermo Fisher Scientific, Inc.
- Boehringer Ingelheim International GmbH
- Infosys Limited
- Charles River Laboratories International, Inc.
- Agilent Technologies, Inc.
- Illumina, Inc.
- Certara, Inc.
- Jubilant Pharmova Limited
Methodology
LOADING...
